- Home
- FHI vs NVCR Comparison
FHI vs NVCR Comparison
Compare FHI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- NVCR
- Stock Information
- Founded
- FHI 1955
- NVCR 2000
- Country
- FHI United States
- NVCR Jersey
- Employees
- FHI N/A
- NVCR N/A
- Industry
- FHI Investment Managers
- NVCR Medical/Dental Instruments
- Sector
- FHI Finance
- NVCR Health Care
- Exchange
- FHI Nasdaq
- NVCR Nasdaq
- Market Cap
- FHI 3.4B
- NVCR 3.2B
- IPO Year
- FHI N/A
- NVCR 2015
- Fundamental
- Price
- FHI $38.18
- NVCR $26.17
- Analyst Decision
- FHI Buy
- NVCR Buy
- Analyst Count
- FHI 6
- NVCR 5
- Target Price
- FHI $42.17
- NVCR $33.40
- AVG Volume (30 Days)
- FHI 669.1K
- NVCR 1.0M
- Earning Date
- FHI 01-30-2025
- NVCR 02-27-2025
- Dividend Yield
- FHI 3.25%
- NVCR N/A
- EPS Growth
- FHI 3.08
- NVCR N/A
- EPS
- FHI 3.16
- NVCR N/A
- Revenue
- FHI $1,598,907,000.00
- NVCR $577,738,000.00
- Revenue This Year
- FHI $2.01
- NVCR $19.13
- Revenue Next Year
- FHI $6.64
- NVCR $5.38
- P/E Ratio
- FHI $12.07
- NVCR N/A
- Revenue Growth
- FHI 0.44
- NVCR 14.63
- 52 Week Low
- FHI $31.24
- NVCR $11.70
- 52 Week High
- FHI $43.92
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- FHI 29.58
- NVCR 41.68
- Support Level
- FHI $38.07
- NVCR $25.46
- Resistance Level
- FHI $39.01
- NVCR $27.70
- Average True Range (ATR)
- FHI 0.79
- NVCR 1.29
- MACD
- FHI -0.25
- NVCR -0.82
- Stochastic Oscillator
- FHI 18.41
- NVCR 10.77
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.